The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study.
Conclusions: The present study supports the feasibility and safety profile of 3HP for the treatment of LTBI in Nunavut.
PMID: 32379538 [PubMed - in process]
Source: International Journal of Circumpolar Health - Category: International Medicine & Public Health Tags: Int J Circumpolar Health Source Type: research
More News: Alcoholism | Canada Health | History of Medicine | International Medicine & Public Health | Statistics | Study